|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
55,671,000 |
Market
Cap: |
79.61(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.2 - $11.21 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Marinus Pharmaceuticals is a pharmaceutical company focused on developing and commercializing products for patients suffering from rare genetic epilepsies and other seizure disorders. The U.S Food and Drug Administration approved the use of ZTALMY® (ganaxolone) oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder in patients two years of age and older. Ganaxolone is being developed in formulations for various routes of administration: intravenous and oral. Ganaxolone acts at both synaptic and extrasynaptic gamma-aminobutyric acid type A receptors, a target known for its anti-seizure, antidepressant and anxiolytic potential.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
21,803 |
21,803 |
38,528 |
41,369 |
Total Sell Value |
$215,409 |
$215,409 |
$374,962 |
$393,504 |
Total People Sold |
5 |
5 |
5 |
8 |
Total Sell Transactions |
5 |
5 |
15 |
18 |
End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hulihan Joseph |
Chief Medical Officer |
|
2022-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
7,718 |
24,868 |
|
- |
|
Ezickson Elan |
Director |
|
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750 |
2,750 |
|
- |
|
Pfanstiel Steven |
Chief Financial Officer |
|
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
16,550 |
16,550 |
|
- |
|
Austin Charles |
Director |
|
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750 |
2,750 |
|
- |
|
Arroyo Santiago |
Director |
|
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750 |
2,750 |
|
- |
|
Mayleben Timothy M |
Director |
|
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750 |
13,875 |
|
- |
|
Nochur Sara |
Director |
|
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750 |
2,750 |
|
- |
|
Fischer Seth H.z. |
Director |
|
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750 |
3,444 |
|
- |
|
Dougherty Michael R |
Director |
|
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750 |
3,312 |
|
- |
|
Manning Martha E |
VP Gen Counsel and Corp Sec. |
|
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
12,867 |
12,867 |
|
- |
|
Vitullo Nicole |
Director |
|
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750 |
6,442 |
|
- |
|
Hulihan Joseph |
Chief Medical Officer |
|
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
17,150 |
17,150 |
|
- |
|
Braunstein Scott |
Chief Executive Officer |
|
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
42,900 |
67,900 |
|
- |
|
Vitullo Nicole |
Director |
|
2021-03-16 |
4 |
A |
$0.00 |
$0 |
D/D |
2,717 |
3,692 |
|
- |
|
Vitullo Nicole |
Director |
|
2021-03-16 |
4 |
D |
$0.00 |
$0 |
I/I |
(17,804) |
0 |
|
- |
|
Vitullo Nicole |
Director |
|
2021-03-15 |
4 |
S |
$15.87 |
$67,448 |
I/I |
(4,250) |
0 |
|
-2% |
|
Vitullo Nicole |
Director |
|
2021-03-12 |
4 |
A |
$0.00 |
$0 |
I/I |
6,192 |
6,192 |
|
- |
|
Vitullo Nicole |
Director |
|
2021-03-12 |
4 |
D |
$0.00 |
$0 |
I/I |
(619,221) |
0 |
|
- |
|
Smith Edward F |
Former VP, CFO & Treasurer |
|
2021-03-09 |
4 |
AS |
$17.80 |
$718,337 |
D/D |
(40,356) |
13,288 |
|
-16% |
|
Smith Edward F |
Former VP, CFO & Treasurer |
|
2021-03-09 |
4 |
OE |
$4.16 |
$149,456 |
D/D |
35,927 |
53,644 |
|
- |
|
Smith Edward F |
CFO |
|
2020-01-30 |
4 |
S |
$2.05 |
$4,879 |
D/D |
(2,380) |
17,717 |
|
-24% |
|
Braunstein Scott |
Chief Executive Officer |
|
2019-12-13 |
4 |
B |
$1.25 |
$125,000 |
D/D |
100,000 |
100,000 |
2.81 |
- |
|
Smith Edward F |
CFO |
|
2019-05-16 |
4 |
AS |
$5.03 |
$121,781 |
D/D |
(24,211) |
20,097 |
|
- |
|
Cashman Christopher Michael |
CEO |
|
2019-03-18 |
4 |
OE |
$1.04 |
$32,928 |
D/D |
31,662 |
271,423 |
|
- |
|
Smith Edward F |
CFO |
|
2019-01-29 |
4 |
S |
$3.06 |
$7,626 |
D/D |
(2,492) |
44,308 |
|
- |
|
129 Records found
|
|
Page 3 of 6 |
|
|